In a Phase 3 trial of 1,879 patients, tirzepatide at all doses was statistically superior to semaglutide 1mg for HbA1c reduction (up to -2.30% vs -1.86%) and produced up to 5.5 kg more weight loss over 40 weeks.
-2.30% HbA1c vs -1.86%Tirzepatide 15mg reduced HbA1c by 0.45 percentage points more than semaglutide 1mg — a clinically and statistically significant difference (p<0.001)
What the researchers found
Tirzepatide was noninferior and superior to semaglutide 1mg: HbA1c reductions of -2.01%, -2.24%, -2.30% (5/10/15mg) vs -1.86% semaglutide. Weight loss differences: -1.9, -3.6, -5.5 kg favoring tirzepatide (all p<0.001).
Why it matters
This is the first head-to-head Phase 3 trial showing a new diabetes drug is superior to semaglutide — the previous best-in-class. It established tirzepatide as the most effective injectable for type 2 diabetes.
The numbers in context
1,879 patients; HbA1c: -2.01/-2.24/-2.30% vs -1.86%; weight: -1.9/-3.6/-5.5 kg more; nausea 17-22% vs 18%; hypoglycemia 0.2-1.7% vs 0.4%; serious AEs 5-7% vs 3%
How the study worked
Open-label, 40-week, Phase 3 RCT (SURPASS-2). 1,879 patients randomized 1:1:1:1 to tirzepatide 5/10/15 mg or semaglutide 1 mg weekly. Primary endpoint: HbA1c change from baseline to 40 weeks. NCT03987919.
Who was studied
Adults with type 2 diabetes on metformin, mean HbA1c 8.28%, mean weight 93.7 kg
What this study cannot tell us
Open-label design (not blinded). Semaglutide dose was 1 mg (not the higher 2.4 mg dose used for weight management). Eli Lilly-funded. 40-week duration — longer-term comparisons needed. Serious adverse events slightly higher with tirzepatide (5-7% vs 3%).
How to read the evidence
High evidence: large Phase 3 RCT with 1,879 patients, 40-week duration, and robust statistical methodology. Open-label design is the main limitation.
When this study was published
Published 2021. Tirzepatide has since been approved as Mounjaro (diabetes) and Zepbound (obesity). Additional data from SURPASS and SURMOUNT programs continues to accumulate.
The bigger picture
SURPASS-2 marked a paradigm shift in diabetes treatment, establishing that dual GIP/GLP-1 receptor agonism produces better outcomes than GLP-1 alone. Tirzepatide (now marketed as Mounjaro) has since been approved for both diabetes and obesity.
Questions still open
- Would tirzepatide still be superior compared to semaglutide 2.4 mg?
- What drives tirzepatide's additional benefit — the GIP receptor activation, the dual mechanism, or both?
- Are the slightly higher serious adverse events with tirzepatide clinically meaningful?
Common questions
Is tirzepatide better than semaglutide?
What is the difference between tirzepatide and semaglutide?
Read the original research
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
The New England journal of medicine, 385(6), 503-515
Citation
Frías, Juan P; Davies, Melanie J; Rosenstock, Julio; Pérez Manghi, Federico C; Fernández Landó, Laura; Bergman, Brandon K; Liu, Bing; Cui, Xuewei; Brown, Katelyn. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. The New England journal of medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519